Gossamer Bio Inc. (GOSS)
0.17
-0.01 (5.56%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: Opaleye Management Inc.
July 29, 2026 4:06 PM - SEC Filing
Form SCHEDULE 13G/A Gossamer Bio, Inc. Filed by: BlackRock, Inc.
July 29, 2026 3:21 PM - SEC Filing
Leerink Upgrades Gossamer Bio Inc. (GOSS) to Outperform
July 28, 2026 2:36 AM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Jul 23
July 27, 2026 4:01 PM - SEC Filing
Gossamer Bio plans NDA submission for seralutinib in September 2026
July 27, 2026 7:02 AM - StreetInsider
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
July 27, 2026 7:00 AM - BizWire
Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.
July 24, 2026 9:15 PM - SEC Filing
Form 8-K Gossamer Bio, Inc. For: Jul 14
July 15, 2026 6:18 AM - SEC Filing
Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.
July 1, 2026 9:24 PM - SEC Filing
Gossamer Bio sets conversion rate for 2030 convertible notes
July 1, 2026 9:03 AM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Jul 01
July 1, 2026 9:01 AM - SEC Filing
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
July 1, 2026 9:00 AM - BizWire
Gossamer Bio Inc. (GOSS) PT Lowered to $2 at H.C. Wainwright
June 26, 2026 6:40 AM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Jun 17
June 17, 2026 8:01 AM - SEC Filing
Gossamer Bio exchange offer closes with $18.9M in notes remaining
June 17, 2026 8:01 AM - StreetInsider
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
June 17, 2026 8:00 AM - BizWire
Form SCHEDULE 13D Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.
June 11, 2026 9:13 PM - SEC Filing
Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: DeepCurrents Investment Group LLC
June 11, 2026 8:11 PM - SEC Filing
Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: 683 Capital Management, LLC
June 11, 2026 4:55 PM - SEC Filing
Form DEF 14A Gossamer Bio, Inc. For: Jul 14
June 9, 2026 4:19 PM - SEC Filing
Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: Context Capital Management, LLC
June 9, 2026 8:44 AM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Jun 04 Filed by: Quisel John D
June 5, 2026 5:46 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Jun 04 Filed by: Drynan Skye
June 5, 2026 4:31 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Jun 04 Filed by: Daniel Thomas O
June 5, 2026 4:30 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Jun 04 Filed by: Cox Russell J.
June 5, 2026 4:30 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Jun 04 Filed by: Milligan Sandra
June 5, 2026 4:28 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Jun 04 Filed by: Nathan Steven D
June 5, 2026 4:28 PM - SEC Filing
Gossamer Bio completes early settlement of convertible notes exchange
June 5, 2026 6:09 AM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Jun 03
June 5, 2026 6:04 AM - SEC Filing
Form 8-K Gossamer Bio, Inc. For: Jun 04
June 5, 2026 6:01 AM - SEC Filing
Gossamer Bio reports 90.5% participation in convertible note exchange
June 3, 2026 8:01 AM - StreetInsider
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
June 3, 2026 8:00 AM - BizWire
Form 8-K Gossamer Bio, Inc. For: Jun 02
June 2, 2026 8:01 AM - SEC Filing
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
June 2, 2026 8:00 AM - BizWire
Gossamer Bio Inc. (GOSS) PT Lowered to $0.28 at Barclays
May 19, 2026 3:58 AM - StreetInsider
Gossamer Bio Inc. (GOSS) Misses Q1 EPS by 3c
May 18, 2026 7:51 AM - StreetInsider
Form PRE 14A Gossamer Bio, Inc. For: May 18
May 18, 2026 7:09 AM - SEC Filing
Form DEFA14A Gossamer Bio, Inc.
May 18, 2026 7:08 AM - SEC Filing
Form 8-K Gossamer Bio, Inc. For: May 18
May 18, 2026 7:07 AM - SEC Filing
Gossamer Bio launches debt exchange offer to eliminate $120 million
May 18, 2026 7:06 AM - StreetInsider
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
May 18, 2026 7:05 AM - BizWire
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
May 18, 2026 7:00 AM - BizWire
Form 10-Q Gossamer Bio, Inc. For: Mar 31
May 15, 2026 4:04 PM - SEC Filing
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
May 15, 2026 7:01 AM - BizWire
Form SCHEDULE 13G/A Gossamer Bio, Inc. Filed by: Octagon Capital Advisors LP
May 14, 2026 4:02 PM - SEC Filing
Full Article List
